These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 37846599

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?
    Menzies-Gow A, Wechsler ME, Brightling CE.
    Respir Res; 2020 Oct 15; 21(1):268. PubMed ID: 33059715
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types.
    Panettieri R, Lugogo N, Corren J, Ambrose CS.
    J Asthma Allergy; 2024 Oct 15; 17():219-236. PubMed ID: 38524099
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Thymic Stromal Lymphopoietin and Tezepelumab in Airway Diseases: From Physiological Role to Target Therapy.
    Bagnasco D, De Ferrari L, Bondi B, Candeliere MG, Mincarini M, Riccio AM, Braido F.
    Int J Mol Sci; 2024 May 29; 25(11):. PubMed ID: 38892164
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tezepelumab: an anti-thymic stromal lymphopoietin monoclonal antibody for the treatment of asthma.
    Shinkai M, Yabuta T.
    Immunotherapy; 2023 Dec 29; 15(17):1435-1447. PubMed ID: 37724378
    [Abstract] [Full Text] [Related]

  • 15. Epithelial cell alarmin cytokines: Frontline mediators of the asthma inflammatory response.
    Duchesne M, Okoye I, Lacy P.
    Front Immunol; 2022 Dec 29; 13():975914. PubMed ID: 36311787
    [Abstract] [Full Text] [Related]

  • 16. Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma.
    Pelaia C, Pelaia G, Crimi C, Maglio A, Gallelli L, Terracciano R, Vatrella A.
    Int J Mol Sci; 2021 Apr 22; 22(9):. PubMed ID: 33922072
    [Abstract] [Full Text] [Related]

  • 17. Oxidative Stress Attenuates TLR3 Responsiveness and Impairs Anti-viral Mechanisms in Bronchial Epithelial Cells From COPD and Asthma Patients.
    Menzel M, Ramu S, Calvén J, Olejnicka B, Sverrild A, Porsbjerg C, Tufvesson E, Bjermer L, Akbarshahi H, Uller L.
    Front Immunol; 2019 Apr 22; 10():2765. PubMed ID: 31849956
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Tezepelumab (Tezspire®) : new biological treatment of severe asthma].
    Schleich F, Sabbe M, Moermans C, Louis R.
    Rev Med Liege; 2024 Jan 22; 79(1):60-64. PubMed ID: 38223972
    [Abstract] [Full Text] [Related]

  • 20. House dust mite sensitization and exposure affects bronchial epithelial anti-microbial response to viral stimuli in patients with asthma.
    Cerps S, Sverrild A, Ramu S, Nieto-Fontarigo JJ, Akbarshahi H, Menzel M, Andersson C, Tillgren S, Hvidtfeldt M, Porsbjerg C, Uller L.
    Allergy; 2022 Aug 22; 77(8):2498-2508. PubMed ID: 35114024
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.